Clinical Variability in Cardiovascular Disease Risk Factor Screening and Management in Adolescent and Young Adult Women with Polycystic Ovary Syndrome

Journal of Pediatric and Adolescent Gynecology

Volumn 28, Issue 5, 2015, Pages 317-323

  Baer, Tamara E ^a   Milliren, Carly E ^a   Walls, Courtney ^b   DiVasta, Amy D ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b Decision Resources Group   (United States)

Author keywords

Adolescents; Cardiovascular risk factors; Insulin resistance; Obesity; PCOS

Indexed keywords

ESTROGEN; ESTROGEN PLUS PROGESTIN; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ACANTHOSIS NIGRICANS; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CLINICAL FEATURE; DIET RESTRICTION; DIETITIAN; EXERCISE; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HUMAN; LABORATORY TEST; LIFESTYLE MODIFICATION; LONGITUDINAL STUDY; LOW CARBOHYDRATE DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SELF REPORT; YOUNG ADULT; BODY WEIGHT; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERINSULINISM; INSULIN RESISTANCE; MASS SCREENING; OBESITY; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MASS SCREENING; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84983201182     PISSN: 10833188     EISSN: 18734332     Source Type: Journal    
DOI: 10.1016/j.jpag.2014.09.010     Document Type: Article

References (27)

1. Orsino A., Van Eyk N., Hamilton J. Clinical features, investigations and management of adolescents with polycystic ovary syndrome Paediatr Child Health 2005, 10:602.
2. Centers for Disease Control and Prevention, National Center for Health Statistics: Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 5-year age groups, by race and sex: United States, 2010. Available: . Accessed April 17, 2013. http://www.cdc.gov/nchs/data/dvs/LCWK1_2010.pdf.
3. Gambineri A., Pelusi C., Vicennati V., et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002, 26:883.
4. Barbieri R.L., Smith S., Ryan K.J. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988, 50:197.
5. Silfen M.E., Denburg M.R., Manibo A.M., et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003, 88:4682.
6. Morales A.J., Laughlin G.A., Butzow T., et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996, 81:2854.
7. Nestler J.E. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008, 358:47.
8. Hart R., Doherty D.A., Mori T., et al. Extent of metabolic risk in adolescent girls with features of polycyctic ovary syndrome. Fertil Steril 2011, 95:2347.
9. De Leo V., Musacchio M.C., Morgante G., et al. Metformin treatment is effective in obese teenage girls with PCOS. Humanit Rep 2006, 21:2252.
10. Palmert M.R., Gordon C.M., Kartashov A.I., et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:1017.
11. Coviello A.D., Legro R.S., Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006, 91:492.
12. Shroff R., Kerchner A., Maifeld M., et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007, 92:4609.
13. Azziz R., Carmina E., Dewailly D., et al Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91:4237.
14. Barlow S.E. Expert Committee: Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report Pediatrics 2007, 120:S164.
15. National Heart, Lung, and Blood Institute, National Institutes of Health: Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. September 1998, NIH publication No. 98-4083. Available: . Accessed August 21, 2014. http://www.nhlbi.nih.gov/files/docs/guidelines/ob_gdlns.pdf.
16. US Department of Health and Human Services: The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Available: . Accessed October 11, 2013. http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.pdf.
17. American Academy of Pediatrics Expert panel on integrated guidelines for cardiovascular health and risk in children and adolescents: summary report Pediatrics 2011, 128:S213.
18. Bekx M.T., Connor E.C., Allen D.B. Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2010, 23:7.
19. Geier L.M., Bekx M.T., Connor E.L. Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2012, 25:367.
20. Legro R.S., Kunselman A.R., Dunaif A Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001, 111:607.
21. Mather K.J., Kwan F., Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000, 73:150.
22. Bonny A.E., Appelbaum H., Connor E.L., et al. Clinical variability in approaches to polycystic ovary syndrome. J Pediatr Adolesc Gynecol 2012, 25:259.
23. Wild R.A., Carmina E., Diamanti-Kandarakis E., et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary disease: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010, 95:2038.
24. Flannery C.A., Rackow B., Cong X., et al Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI Pediatr Diabetes 2013, 14:42.
25. ACOG Practice Bulletin No.108 Polycystic ovary syndrome. Obstet Gynecol 2009, 114:936.
26. Pasquali R., Antenucci D., Casimirri F., et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989, 68:173.
27. Practice Committee of American Society of Reproductive Medicine Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril 2008, 90:S69.